Cargando…
Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts
We aimed to determine the effect of SGI-110 on methylation and expression of the cancer testis antigens (CTAs) NY-ESO-1 and MAGE-A in epithelial ovarian cancer (EOC) cells in vitro and in vivo and to establish the impact of SGI-110 on expression of major histocompatibility (MHC) class I and Intracel...
Autores principales: | Srivastava, Pragya, Paluch, Benjamin E, Matsuzaki, Junko, James, Smitha R, Collamat-Lai, Golda, Taverna, Pietro, Karpf, Adam R, Griffiths, Elizabeth A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623048/ https://www.ncbi.nlm.nih.gov/pubmed/25793777 http://dx.doi.org/10.1080/15592294.2015.1017198 |
Ejemplares similares
-
Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment
por: Covre, Alessia, et al.
Publicado: (2013) -
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy
por: Srivastava, Pragya, et al.
Publicado: (2016) -
Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies
por: Xu, Cong, et al.
Publicado: (2017) -
DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma
por: Li, Juan, et al.
Publicado: (2022) -
Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma
por: Jueliger, Simone, et al.
Publicado: (2016)